Trial Profile
An Open-Label, Phase 2 Trial to Investigate the Humoral and Cell-Mediated Immune Responses and Safety of a Tetravalent Dengue Vaccine Candidate (TDV) Administered Subcutaneously in Flavivirus-Naïve and Dengue-Immune Healthy Adults
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 12 Apr 2024
Price :
$35
*
At a glance
- Drugs TAK 003 (Primary)
- Indications Dengue
- Focus Pharmacodynamics
- Sponsors Takeda
- 02 Mar 2021 Status changed from active, no longer recruiting to completed.
- 26 Feb 2021 Planned End Date changed from 21 Feb 2021 to 1 Mar 2021.
- 26 Feb 2021 Planned primary completion date changed from 21 Feb 2021 to 1 Mar 2021.